Mott Capital Management, LLC on GRAIL, Inc.
Thesis
Mott Capital held Grail as a way to participate in the emerging market for blood-based multi-cancer early detection tests. Shares surged after a favorable FDA advisory-panel vote, which the manager sees as paving the way toward regulatory approval. Approval could also unlock reimbursement by Medicare and private insurers, expanding commercial adoption. Michael Kramer believes the category is still early in its development and that applying AI could improve the tests’ effectiveness over time.
“With the adoption of AI, these tests are likely to improve over time, making them a desirable tool for detecting cancer.”
Key risks
- The test still requires formal FDA approval following the advisory-panel vote.
- Potential Medicare and private-insurance reimbursement remains uncertain.
- Early-stage testing technology may take time to improve and gain broad adoption.